AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Cullinan Oncology LLC (NASDAQ:CGEM)
7.49 USD
+0.070 0.943%Sponsored Reports
Loading...
| Previous Close (in USD) | 7.42 |
|---|---|
| Change | +0.070 0.943% |
| 52 W H/L (in USD) | 30.189/7.940 |
| EBITDA (in USD) | -187.05M |
| PE Ratio | -- |
| Volume | 73896 |
| Diluted Eps TTM | -2.84 |
| Total Assets (in USD) | 485.096M |
|---|---|
| Total Liabilities (in USD) | 31.201M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 98.434M |
| Market Cap (in USD) | 739.491 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 18.943M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Employees: 85
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Nadim Ahmed | Pres, CEO & Director | 1968 |
| 2. | Mr. Jeffrey Trigilio | CFO & Treasurer | 1985 |
| 3. | Dr. Patrick A. Baeuerle Ph.D. | Chief Scientific Officer | 1958 |
| 4. | Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corp. Sec. | 1978 |
| 5. | Ms. Rose Weldon | VP of Communications | NA |
| 6. | Mr. Steve Andre | Chief HR Officer | NA |
| 7. | Dr. Corinne Savill Ph.D. | Chief Bus. Officer | 1959 |
| 8. | Dr. Jennifer Michaelson Ph.D. | Chief Devel. Officer | 1968 |
| 9. | Ms. Kerry Whalen | Sr. Director of Preclinical & Early Devel. | NA |
| 10. | Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer | 1971 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.087 1.568% | 69.5 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 69.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+10.375 2.258% | 457.73 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+19.140 3.557% | 538.87 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 151.316M | -67.485M | -59.458M | -21.654M | -14.189M |
| Minority Interest | -2.019M | -1.915M | 1.304M | 0.864M | 0.001M |
| Net Income | 111.214M | -65.04M | -50.849M | -20.037M | -14.189M |
| Selling General Administrative | 40.189M | 29.146M | 17.124M | 5.482M | 5.002M |
| Gross Profit | - | 18.943M | - | - | - |
| Reconciled Depreciation | 0.093M | 0.053M | 0.062M | 0.07M | 0.043M |
| Ebit | 144.648M | -68.007M | -60.397M | -22.27M | -14.586M |
| Ebitda | -408.922M | -67.954M | -60.335M | -22.2M | -14.543M |
| Depreciation And Amortization | -553.57M | 0.053M | 0.062M | 0.07M | 0.043M |
| Operating Income | 144.648M | -67.954M | -60.335M | -22.27M | -14.586M |
| Other Operating Expenses | 132.137M | 86.897M | 60.335M | 22.27M | 14.586M |
| Interest Expense | -562.35M | 65.45M | 0.888M | 0M | 0M |
| Tax Provision | 42.121M | - | - | - | - |
| Interest Income | 6.611M | 0.477M | 0.888M | 0.62M | 0.397M |
| Net Interest Income | 6.611M | 0.477M | 0.888M | 0.62M | 0.397M |
| Income Tax Expense | 42.121M | -2.445M | -8.609M | -1.617M | 0.397M |
| Total Revenue | 0M | 18.943M | 0M | 0M | 0M |
| Total Operating Expenses | 132.137M | 86.897M | 60.335M | 22.27M | 14.586M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 6.668M | 0.469M | 0.877M | 0.616M | 0.397M |
| Net Income From Continuing Ops | 109.195M | -65.57M | -59.458M | -21.654M | -14.189M |
| Net Income Applicable To Common Shares | 111.214M | -65.57M | -51.799M | -20.657M | -14.189M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 485.096M | 561.117M | 437.185M | 214.708M | 100.461M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 13.124M | 7.18M | 6.098M | 2.072M | 1.461M |
| Total Liab | 31.201M | 26.088M | 11.811M | 291.046M | 140.37M |
| Total Stockholder Equity | 453.703M | 535.029M | 422.576M | -77.642M | -40.773M |
| Other Current Liab | 24.204M | 18.239M | 8.577M | 4.641M | 1.589M |
| Common Stock | 0.004M | 0.005M | 0.004M | 0.001M | 0.001M |
| Capital Stock | 0.004M | 0.005M | 0.004M | 0.001M | 0.001M |
| Retained Earnings | -200.857M | -47.695M | -158.909M | -93.339M | -41.54M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 0.459M | 6.322M | 2.3M | 0.188M |
| Cash | 98.434M | 550.118M | 430.863M | 168.198M | 63.25M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 28.137M | 22.498M | 11.746M | 14.32M | 2.523M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -94.844M | -544.929M | -430.863M | -168.198M | -63.25M |
| Short Term Debt | 1.44M | 1.599M | - | - | - |
| Short Long Term Debt | - | 0.178M | - | - | - |
| Short Long Term Debt Total | 3.59M | 5.189M | - | - | - |
| Other Stockholder Equity | 654.685M | 585.32M | 582.319M | 15.698M | 0.77M |
| Property Plant Equipment | - | 1.174M | 0.077M | 0.13M | 0.182M |
| Total Current Assets | 480.191M | 474.472M | 296.564M | 212.278M | 100.091M |
| Long Term Investments | 0M | 80.882M | 140.397M | - | - |
| Short Term Investments | 368.633M | 311.14M | 230.692M | 42.008M | 35.38M |
| Net Receivables | 5.4M | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | -5.4M | - | - | - | - |
| Accounts Payable | 2.493M | 2.66M | 3.169M | 9.679M | 0.934M |
| Accumulated Other Comprehensive Income | -0.129M | -2.601M | -0.838M | -0.002M | -0.004M |
| Non Currrent Assets Other | 0.459M | 0.459M | 0.147M | 2.3M | 0.188M |
| Non Current Assets Total | 4.905M | 86.645M | 140.621M | 2.43M | 0.37M |
| Capital Lease Obligations | 3.59M | 5.011M | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -24.983M | -333.775M | -6.86M | -35.4M | -0.261M |
| Total Cashflows From Investing Activities | 248.975M | -333.775M | -5.42M | -35.4M | -0.261M |
| Total Cash From Financing Activities | -25.933M | 268.784M | 140.14M | 85.715M | -0.029M |
| Net Income | 109.195M | -67.485M | -59.458M | -21.654M | -14.189M |
| Change In Cash | 96.378M | -108.424M | 104.948M | 29.418M | -13.839M |
| Begin Period Cash Flow | 59.774M | 168.198M | 63.25M | 33.832M | 47.671M |
| End Period Cash Flow | 156.152M | 59.774M | 168.198M | 63.25M | 33.832M |
| Total Cash From Operating Activities | -126.664M | -43.433M | -29.772M | -20.897M | -13.549M |
| Depreciation | 0.093M | 0.053M | 0.062M | 0.07M | 0.043M |
| Other Cashflows From Investing Activities | 275.091M | - | 1.45M | 1.45M | 1.45M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | -23.733M | 271.472M | -0.213M | -0.378M | -0.021M |
| Other Cashflows From Financing Activities | -23.739M | 1.516M | 140.353M | 86.093M | -0.009M |
| Capital Expenditures | 1.133M | 1.133M | 0.01M | 0.02M | 0.261M |
| Change In Working Capital | 11.176M | -3.541M | 6.851M | 0.135M | 0.345M |
| Other Non Cash Items | -275.085M | 0.067M | 7.63M | 0.539M | 0.252M |
| Free Cash Flow | -127.797M | -43.433M | -29.782M | -20.917M | -13.81M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 8 months ago | 1504501 |
| 2. | iShares Russell 2000 ETF | 7 months ago | 1451725 |
| 3. | SPDR® S&P Biotech ETF | 7 months ago | 1234098 |
| 4. | Franklin Biotechnology Discv A(acc)USD | 8 months ago | 842143 |
| 5. | AB Small Cap Growth A | 8 months ago | 824682 |
| 6. | Franklin US Small Cap Growth Equity | 9 months ago | 791566 |
| 7. | Franklin Small Cap Growth Adv | 9 months ago | 791566 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 8 months ago | 760997 |
| 9. | Fidelity Small Cap Index | 9 months ago | 525505 |
| 10. | Franklin Biotechnology Discovery A | 9 months ago | 483951 |
| 11. | iShares Russell 2000 Growth ETF | 7 months ago | 410993 |
| 12. | Xtrackers S&P 500 Swap ETF 1C | 8 months ago | 310122 |
| 13. | Fidelity Extended Market Index | 8 months ago | 292057 |
| 14. | State St Russell Sm/Mid Cp® Indx NL Cl C | 8 months ago | 274338 |
| 15. | iShares Biotechnology ETF | 7 months ago | 264450 |
| 16. | Biotech Growth Ord | 10 months ago | 263157 |
| 17. | Schwab US Small-Cap ETF™ | 7 months ago | 251411 |
| 18. | Vanguard Russell 2000 ETF | 8 months ago | 234023 |
| 19. | CT (Lux) American Smaller Com 9U USD | 8 months ago | 219041 |
| 20. | CT American Smaller Coms(US) InstAccGBP | 8 months ago | 203177 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | MPM Oncology Impact Management LP | 9 months ago | 7648268 |
| 2. | Bvf Inc | 9 months ago | 5750683 |
| 3. | BlackRock Inc | 1 year ago | 3550207 |
| 4. | Deerfield Management Co | 9 months ago | 3280000 |
| 5. | Nextech Invest AG | 9 months ago | 1141145 |
| 6. | Orbimed Advisors, LLC | 9 months ago | 1070055 |
| 7. | Marshall Wace Asset Management Ltd | 9 months ago | 1053764 |
| 8. | Vanguard Group Inc | 9 months ago | 2998714 |
| 9. | State Street Corp | 9 months ago | 2337222 |
| 10. | Paradigm Biocapital Advisors LP | 9 months ago | 2321013 |
| 11. | Franklin Resources Inc | 9 months ago | 2191262 |
| 12. | Blue Owl Capital Holdings LP | 9 months ago | 2010972 |
| 13. | Citadel Advisors Llc | 9 months ago | 1955257 |
| 14. | AllianceBernstein L.P. | 9 months ago | 1854410 |
| 15. | RTW INVESTMENTS, LLC | 9 months ago | 1705960 |
| 16. | Holocene Advisors, LP | 9 months ago | 1533579 |
| 17. | VR Adviser, LLC | 9 months ago | 1379965 |
| 18. | Adage Capital Partners Gp LLC | 9 months ago | 1355876 |
| 19. | Geode Capital Management, LLC | 9 months ago | 1208421 |
| 20. | BRAIDWELL LP | 9 months ago | 1176173 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...